Answers are grounded in this paper and cite their sources.
B7-H3 CAR T cells could represent an exciting therapeutic option for patients with certain lethal relapsed or refractory pediatric malignancies, and should be tested in carefully designed clinical trials.
No takes yet. Share an insight, caveat, or question.
Majzner et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: